In this video lecture, Dr. Bruno Fattizzo discusses:
- The heterogeneous clinical manifestations of cold agglutinin disease, including anemia, hemolysis, cold-induced circulatory symptoms, and their impact on patients’ daily lives.
- The major complications of CAD, particularly thromboembolism, mortality, and infection, and how disease activity and treatment contribute to these risks.
- Practical strategies for reducing complications through appropriate treatment selection, infection prophylaxis, and minimizing unnecessary immunosuppression.
Dr. Bruno Fattizzo is a Hematologist and Assistant Professor at Policlinico Hospital and University of Milan, Italy. His clinical and research work is mainly focused on autoimmune cytopenias, autoimmune hemolytic anemia (AIHA), immune thrombocytopenia, autoimmune neutropenia, and Evans syndrome, and on bone marrow failure syndromes such as paroxysmal nocturnal hemoglobinuria (PNH), aplastic anemia, and myelodysplastic syndromes (MDS). He spent a research period at King’s College Hospital in London working on bone marrow failure syndromes and studying the clinical and prognostic implications of small PNH clones. He is the author of several publications on indexed Journals and lead of clinical trials with novel drugs in AIHA, PNH, and MDS.
(Video Lecture Summary)
Introduction
Dr. Bruno Fattizzo reviews the disease burden and complications associated with cold agglutinin disease (CAD). He emphasizes that CAD is a chronic, heterogeneous disorder whose impact extends beyond hemolytic anemia to include cold-induced circulatory symptoms, thromboembolic complications, infections, and substantial effects on quality of life. Understanding both disease-related and treatment-related complications is essential for optimizing long-term management.
Clinical Manifestations of CAD
Dr. Fattizzo begins by reviewing the diverse clinical phenotype of CAD. Symptoms generally fall into two major categories. The first relates to anemia and chronic hemolysis, producing fatigue, shortness of breath, impaired daily functioning, jaundice, dark urine, and complications such as gallstones. The second reflects the presence of pathogenic cold agglutinins and typically occurs after cold exposure. These manifestations include Raynaud-like symptoms, acrocyanosis, and bluish discoloration of exposed areas such as the nose, ears, fingers, and toes. While most patients present with hemolytic anemia, a substantial proportion also experience clinically significant circulatory symptoms, illustrating the heterogeneous nature of the disease.
Heterogeneity and Variability of Disease Severity
Drawing on epidemiologic studies from Nordic populations, Dr. Fattizzo highlights the broad spectrum of disease severity observed in CAD. Some patients have compensated hemolysis with near-normal hemoglobin levels, whereas others develop moderate or severe anemia. Importantly, disease severity also varies over time within individual patients. Episodes of infection, surgery, trauma, and the accumulation of comorbidities can all increase complement activation or impair bone marrow compensation, leading to worsening hemolysis and more severe anemia. He notes that CAD should be viewed as a chronic, relapsing disease driven by a persistent clonal B-cell population capable of producing pathogenic cold agglutinins throughout the patient’s lifetime.
Severe Anemia and Transfusion
Dr. Fattizzo discusses the frequency of severe anemia during the course of CAD and emphasizes that anemia severity does not necessarily correspond to transfusion requirements. Real-world data demonstrate that many patients with hemoglobin levels below 8 g/dL are never transfused, reflecting the generally restrictive approach to transfusion in autoimmune hemolytic anemia. Conversely, some patients may receive chronic transfusions before the underlying diagnosis of CAD is recognized. He encourages clinicians evaluating chronic anemia, particularly in transfusion-dependent patients, to consider hemolysis testing and direct antiglobulin testing as part of the diagnostic workup.
Fatigue and Quality of Life
Fatigue is one of the most burdensome symptoms experienced by patients with CAD. Dr. Fattizzo notes that fatigue reflects not only anemia but also the overall burden of chronic hemolysis and disease activity. Using FACIT-Fatigue scores, patients with CAD demonstrate levels of fatigue comparable to those seen in cancer-related anemia and paroxysmal nocturnal hemoglobinuria, underscoring the significant impact of the disease on quality of life.
Thromboembolic Complications
One of the major themes of the lecture is the increased risk of thromboembolism in CAD. Approximately one in five patients experiences either venous or arterial thromboembolic events during the course of disease. Multiple epidemiologic studies from Denmark, Japan, and the United States consistently demonstrate a two- to threefold increased thrombotic risk compared with the general population. Dr. Fattizzo explains that thrombosis appears closely linked to disease activity. Severe hemolysis, elevated LDH, recurrent disease requiring multiple therapies, and treatment-related complications all contribute to increased thrombotic risk. The first 100 days following diagnosis represent a particularly vulnerable period, during which patients often experience the greatest hemolytic activity and receive intensive treatment.
Mortality Risk
The lecture also reviews the relationship between disease severity and mortality. Progressive anemia and increasing markers of hemolysis are associated with substantially higher mortality risk. Compared with patients without anemia, those with moderate anemia have approximately a sevenfold increase in mortality risk, while patients with severe anemia have an even greater risk. Elevated bilirubin and LDH similarly identify patients at higher risk for adverse outcomes. Long-term observational studies demonstrate that the increased mortality associated with CAD persists for many years after diagnosis.
Treatment-Related Complications
Dr. Fattizzo emphasizes that not all complications arise directly from the disease itself. Many serious infections are iatrogenic and reflect prolonged or repeated immunosuppressive therapy. High-dose corticosteroids remain an important contributor to infectious complications despite current recommendations discouraging their routine use in CAD. Similarly, chemoimmunotherapy regimens such as rituximab combined with bendamustine or fludarabine may produce significant neutropenia and serious infections. Because of these risks, he advocates minimizing repeated courses of immunosuppressive therapy whenever possible and using more targeted approaches when appropriate.
Infection Prevention and Supportive Care
For patients receiving rituximab or intensive immunosuppression, Dr. Fattizzo recommends appropriate antimicrobial prophylaxis, including measures to prevent Pneumocystis jirovecii pneumonia and herpesvirus reactivation. Patients treated with complement inhibitors such as sutimlimab require vaccination against encapsulated organisms before treatment and ongoing revaccination according to local guidelines. Even with vaccination, clinicians should remain vigilant for infection, particularly in patients with prior exposure to immunosuppressive therapies. He also reviews less common but clinically important complications, including acute kidney injury during severe hemolytic crises and Evans syndrome, both of which are associated with worse clinical outcomes.
Conclusion
Dr. Fattizzo concludes that CAD is a complex chronic disease whose burden extends far beyond anemia alone. Patients experience highly variable combinations of hemolysis, cold-induced circulatory symptoms, fatigue, thromboembolic events, and treatment-related complications. Effective management requires not only controlling hemolysis but also recognizing complications early, minimizing unnecessary immunosuppression, implementing appropriate prophylactic measures, and selecting targeted therapies that reduce both disease burden and treatment toxicity.